How often is cancer detected when serum PSA is elevated? What factors affect the prostate cancer detection rate?


The detection rate of prostate cancer is influenced by several factors: clinical features including the serum PSA level and an abnormal digital rectal examination (DRE); the number of biopsy cores examined; and the volume of the prostate. Among men with serum PSA < 4ng/ml, 4–10ng/ml, and >10ng/ml, cancer detection rates by prostate needle core biopsy (PNB) are approximately 15%, 25%, and 60%, respectively. Men with low screening PSA (<4 ng/ml) and treated with radical prostatectomy have smaller cancers, lower Gleason scores, lower pathologic tumor stages, and lower PSA recurrence rates than men with higher PSA levels (≥4 ng/ml). If the initial serum PSA values are >10ng/ml, cancers are pathologically in more advanced stages. Cancers detected with an abnormal DRE are more frequently in advanced stages than those discovered by PSA screening.


Prostate Cancer Cancer Detection Rate Radical Prostatectomy Specimen Sextant Biopsy Abnormal Digital Rectal Examination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi LR, Dalkin BL, Waters WB, MacFarlane MT, Southwick PC (1994) Comparison of digital rectal examination and serum prostate-specific antigen in the early detection of prostate cancer; results of a multicenter clinical trial of 6,630 men. J Urol 151:1283–1290.PubMedGoogle Scholar
  2. 2.
    Catalona WJ, Smith DS, Ratliff TL, Basler JW (1993) Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270:948–954.PubMedCrossRefGoogle Scholar
  3. 3.
    Punglia RS, D’Amico AV, Catalona WJ, Roehl KA, Kunz KM (2003) Effect of verification bias on screening for prostate cancer by measurement of prostatespecific antigen. N Engl J Med 349:335–342.PubMedCrossRefGoogle Scholar
  4. 4.
    Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350:2239–2246.PubMedCrossRefGoogle Scholar
  5. 5.
    Datta MW, Dhir R, Dobbin K, Bosland MC, Melamed J, Becich MJ, Orenstein JM, Kajdacsy-Balla AA, Patel A, Macias V, Berman JJ (2005) Prostate cancer in patients with screening serum prostate specific antigen values less than 4.0 ng/dl: results from the cooperative prostate cancer tissue resource. J Urol 173:1546–1551.PubMedCrossRefGoogle Scholar
  6. 6.
    Carter HB (2004) Prostate cancers in men with low PSA levels—must we find them? N Engl J Med 350: 2292–2294.PubMedCrossRefGoogle Scholar
  7. 7.
    Gore JL, Shariat SF, Miles BJ, Kadmon D, Jiang N, Wheeler TM, Slawn KM (2001) Optimal combinations of systemic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 165:1554–1559.PubMedCrossRefGoogle Scholar
  8. 8.
    Eskew LA, Bare RL, McCullough DL (1997) Systemic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of prostate. J Urol 157:199–203.PubMedCrossRefGoogle Scholar
  9. 9.
    Babaian RJ, Toi A, Kamoi K, Troncoso P, Sweet J, Evans R, Johnston D, Chen M (2000) A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy. J Urol 163:152–157.PubMedCrossRefGoogle Scholar
  10. 10.
    Emiliozzi P, Scarpone P, DePaula F, Pizzo M, Federico G, Pansandoro A, Martini M, Pansandoro V (2004) The incidence of prostate cancer in men with prostate specific antigen greater than 4.0 ng/ml: a randomized study of 6 versus 12 core transperitoneal prostate biopsy. J Urol 171:197–199.PubMedCrossRefGoogle Scholar
  11. 11.
    Presti JC Jr, O’Dowd GL, Miller MC, Masttu R, Veltri RW (2003) Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study. J Urol 165:125–129.CrossRefGoogle Scholar
  12. 12.
    Levine MA, Ittman M, Melamed J, Lepor H (1998) Two consecutive sets of transrectal ultrasound guided sextant biopsies of prostate for the detection of prostate cancer. J Urol 159:471–476.PubMedCrossRefGoogle Scholar
  13. 13.
    Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ, Busch C (1997) The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50:562–566.PubMedCrossRefGoogle Scholar
  14. 14.
    Naughton CK, Smith DS, Humphrey PA, Catalona WL, Keetch DW (1998) Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores: a retrospective study. Urology 52:808–813.PubMedCrossRefGoogle Scholar
  15. 15.
    Singh H, Canto EI, Shariat SF, Kadmon D, Miles BJ, Wheeler TM, Slawn KM (2004) Six additional systemic lateral cores enhance sextant biopsy prediction of pathological features at radical prostatectomy. J Urol 171:204–209.PubMedCrossRefGoogle Scholar
  16. 16.
    Naughton CK, Miller DC, Mager DE, Ornstein DK, Catalona WJ (2000) A prospective randomized trial comparing 6 versus 12 prostate biopsy cores: impact on cancer detection. J Urol 164:388–392.PubMedCrossRefGoogle Scholar
  17. 17.
    Lerner SP, Atkinson N (2000) Editorial comment. J Urol 164:392.Google Scholar
  18. 18.
    Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, Marberger M (2000) Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1051 men. J Urol 163:1144–1149.PubMedCrossRefGoogle Scholar
  19. 19.
    Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M, Fakhari M, Seitz C, Susani M, Borkowski A, Boccon-Gibod L, Schulman CC, Marberger M (2001) Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3, and 4: when should we stop? J Urol 166:1679–1683.PubMedCrossRefGoogle Scholar
  20. 20.
    Levine MA, Ittman M, Melamed J, Lepor H (1998) Two consecutive sets of transrectal ultrasound guided sextant biopsies of the prostate for the detection of prostate cancer. J Urol 159:471–476.PubMedCrossRefGoogle Scholar
  21. 21.
    Rietbergen JBW, Boeken Kruger AE, Hoedemaker RF, Bangma CH, Kirkels WJ, Schroeder FH (1998) Repeat screening for prostate cancer after 1-year follow-up in 984 biopsied men: clinical pathological features of detected cancer. J Urol 160:2121–2125.PubMedCrossRefGoogle Scholar
  22. 22.
    Eskicorapci SY, Guliyev F, Akdogan B, Dogan HS, Ergen A, Ozen H (2005) Individualization of the biopsy protocol accounting to the prostate gland volume for prostate cancer detection. J Urol 173:1536–1540.PubMedCrossRefGoogle Scholar
  23. 23.
    Keetch DW, Catalona WJ, Smith DS (1994) Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. J Urol 151:1571–1574.PubMedGoogle Scholar
  24. 24.
    Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EP, Parson RE, Gasior GH, Loveland KG, Southwick PC (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostate disease: a prospective multicenter clinical trial. JAMA 279:1542–1547.PubMedCrossRefGoogle Scholar
  25. 25.
    Fowler JE Jr, Bigler SA, Miles D, Yalkut DA (2000) Predictor of first repeat biopsy cancer detection with suspected local stage prostate cancer. J Urol 163:813–818.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Personalised recommendations